Abstract P6-04-14: Integrating whole genome sequencing data with RNAseq, pathway analysis, and quantitative proteomics to determine prognosis after standard adjuvant treatment with trastuzumab and chemotherapy in primary breast cancer patients

@article{Benz2016AbstractPI,
  title={Abstract P6-04-14: Integrating whole genome sequencing data with RNAseq, pathway analysis, and quantitative proteomics to determine prognosis after standard adjuvant treatment with trastuzumab and chemotherapy in primary breast cancer patients},
  author={S. Benz and S. Rabizadeh and F. Cecchi and M. Beckman and S. Brucker and A. Hartmann and J. Golovato and T. Hembrough and W. Janni and B. Rack and J. Z. Sanborn and A. Schneeweiss and Charles J. Vaske and P. Soon-Shiong and P. Fasching},
  journal={Cancer Research},
  year={2016},
  volume={76}
}
Background: Despite improvements in the treatment of HER2+ breast cancer (BC), almost all patients (pts) progress in the metastatic setting. Three examples of resistance mechanisms are: PI3K mutations, lack of ADCC, or low expression of HER2. We recently showed that among 237 pts who had HER2 amplifications, 49% had normal or low levels of HER2 RNA. In addition, quantification of HER2 protein by selected reaction monitoring mass spectrometry (SRM-MS) accurately predicted HER2 expression status… Expand